Stock Events

Stock Events

Nemaura Medical 

$0
9
+$0+0% Friday 20:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
500
Avg. Volume
1,677
Mkt Cap
5,779.8
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22NovExpected
Q4 2022
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
-0.18
-0.14
-0.09
-0.05
Expected EPS
-0.11
Actual EPS
N/A

Financials

-18,368.83%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
154,000Revenue
-28.29MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NMRD. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Dexcom
DXCM
Mkt Cap24.27B
DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems, directly competing with Nemaura Medical's non-invasive glucose monitoring technology.
Abbott Laboratories
ABT
Mkt Cap178.76B
Abbott Laboratories offers the FreeStyle Libre, a CGM system that competes with Nemaura's glucose monitoring solutions.
Tandem Diabetes Care
TNDM
Mkt Cap945.97M
Tandem Diabetes Care, Inc. manufactures and sells insulin pumps and other diabetes management devices, competing in the broader diabetes care market.
Insulet
PODD
Mkt Cap14.38B
Insulet Corporation produces the Omnipod, an insulin management system, competing in the insulin delivery market alongside Nemaura's diabetes management solutions.
Medtronic
MDT
Mkt Cap111.22B
Medtronic plc offers a range of diabetes management products, including CGM systems and insulin pumps, competing with Nemaura's technologies.
Senseonics
SENS
Mkt Cap288.22M
Senseonics Holdings, Inc. develops and manufactures the Eversense CGM system, a direct competitor to Nemaura's glucose monitoring products.
Mannkind
MNKD
Mkt Cap770.25M
MannKind Corporation focuses on inhaled insulin products, offering alternative diabetes management solutions that compete with Nemaura's offerings.
Zimmer Biomet
ZBH
Mkt Cap18.01B
Zimmer Biomet Holdings, Inc., while primarily focused on orthopedics, has ventured into diabetes care, potentially competing with Nemaura Medical in the future.

About

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Show more...
CEO
Dr. Dewan Fazlul Hoque Chowdhury Ph.D.
Employees
36
Country
US
ISIN
US6404422080

Listings

OTC Link
US
NMRD

0 Comments

Share your thoughts

FAQ

What is Nemaura Medical stock price today?▼
The current price of NMRD is $0 USD — it has increased by +0% in the past 24 hours. Watch Nemaura Medical stock price performance more closely on the chart.
What is Nemaura Medical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nemaura Medical stocks are traded under the ticker NMRD.
What is Nemaura Medical market cap?▼
Today Nemaura Medical has the market capitalization of 5,779.8
What is Nemaura Medical revenue for the last year?▼
Nemaura Medical revenue for the last year amounts to 154,000 USD.
What is Nemaura Medical net income for the last year?▼
NMRD net income for the last year is -28.29M USD.
How many employees does Nemaura Medical have?▼
As of April 06, 2026, the company has 36 employees.
In which sector is Nemaura Medical located?▼
Nemaura Medical operates in the Health Care sector.
When did Nemaura Medical complete a stock split?▼
The last stock split for Nemaura Medical was on December 05, 2019 with a ratio of 1:10.
Where is Nemaura Medical headquartered?▼
Nemaura Medical is headquartered in New York, US.